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Abstract
Objectives: This study assessed the extent and mechanism of complement activation in community-
acquired sepsis at presentation to the emergency department (ED) and following 24 hours of quantitative
resuscitation.
Methods: A prospective pilot study of patients with severe sepsis and healthy controls was conducted
among individuals presenting to a tertiary care ED. Resuscitation, including antibiotics and therapies to
normalize central venous and mean arterial pressure (MAP) and central venous oxygenation, was per-
formed on all patients. Serum levels of Factor Bb (alternative pathway), C4d (classical and mannose-
binding lectin [MBL] pathway), C3, C3a, and C5a were determined at presentation and 24 hours later
among patients.
Results: Twenty patients and 10 healthy volunteer controls were enrolled. Compared to volunteers, all
proteins measured were abnormally higher among septic patients (C4d 3.5-fold; Factor Bb 6.1-fold; C3
0.8-fold; C3a 11.6-fold; C5a 1.8-fold). Elevations in C5a were most strongly correlated with alternative
pathway activation. Surprisingly, a slight but significant inverse relationship between illness severity (by
sequential organ failure assessment [SOFA] score) and C5a levels at presentation was noted. Twenty-
four hours of structured resuscitation did not, on average, affect any of the mediators studied.
Conclusions: Patients with community-acquired sepsis have extensive complement activation, particu-
larly of the alternative pathway, at the time of presentation that was not significantly reversed by
24 hours of aggressive resuscitation.
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A key pathophysiologic feature of sepsis is thedysregulation of innate immunity, including thecomplement system. Activation of complement pathways during sepsis presumably takes place both bydirect contact with bacterial pathogens and by unregu-lated activation on surfaces of injured host cells such as
endothelial cells.1 There is extensive evidence in animal
models that inappropriate complement activation wors-
ens illness. The primary culprit is believed to be C5a,
which serves as a neutrophil chemoattractant and activa-
tor and provokes deleterious responses in a number of
tissues, including vascular endothelium and smooth
muscle, the heart, and the brain.2,3 At least eight different
strategies targeting either C5a or its primary cellular
receptor have been patented and are at various stages of
preclinical development.4
Most insight into complement and C5a in sepsis
comes from animal models. Much less is known in
humans. C5a levels during sepsis and life-threatening
infection have been reported in fewer than 150 patients
in the past 30 years. There are very few human data
examining the relationship between C5a production
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and other features of acute illness. To our knowledge,
C5a abnormalities at initial presentation and their
changes following resuscitation have never been
reported.
Our intent was twofold; first, we measured, in a
cohort of emergency department (ED) patients with
severe sepsis, the extent of C5a activation at presenta-
tion and at 24 hours after the delivery of a structured
resuscitation protocol. Second, we evaluated the influ-
ence of classical and mannose-binding lectin (MBL)
pathway (marker C4d) and the alternative pathway
(marker Bb) on C5a dysregulation. To place these find-
ings in context with what is known of complement acti-
vation in human sepsis from previous intensive care
unit (ICU)-based studies, we carried out a systemic
review of the available published literature to quantify
the current state of knowledge regarding C5a in human
sepsis. Data from previous reports were formally and




This was a prospective pilot study of a cohort of criti-
cally ill patients and an accompanying set of healthy
control individuals. This study was approved by the
institutional review board. All subjects provided written
consent.
Study Setting and Population
The study took place at a tertiary teaching facility
with > 115,000 ED visits annually. Patients were
enrolled if they had 1) suspected or confirmed infection;
2) any two of four criteria of systemic inflammatory
response; and 3) systolic blood pressure
(sBP) < 90 mm Hg or mean arterial pressure (MAP) < 65
after 20 mL ⁄ kg crystalloid (septic shock) or a whole
blood lactate ‡ 4 mmol ⁄ L (severe sepsis). Exclusion cri-
teria were age < 18 years, pregnancy, established prior
‘‘do not attempt resuscitation’’ orders, any primary
diagnosis other than sepsis, requirement for immediate
surgery, or need for cardiopulmonary resuscitation
prior to enrollment.
Inclusion was not consecutive. Rather, patients were
selected from the ranks of a larger ongoing study in
this population. Given the sparse literature regarding
the relationship between complement activation and ill-
ness severity, cases were selected to provide a wide
range of initial sequential organ failure assessment
(SOFA) scores.5 The available patients with the 10 high-
est and lowest initial scores were selected. Ten healthy
volunteers (no acute illness in the prior 2 weeks, no
current corticosteroids, or immunosuppressive medica-
tions) were also enrolled via a posted advertisement
regarding the study. No formal sample size calculations
were performed. Rather, prior findings in the published
literature were chosen to justify the sample used.
Study Protocol
All sepsis subjects were treated in the ED using a quan-
titative resuscitation protocol that required normaliza-
tion of the central venous pressure, MAP, and central
venous oxygen saturation (ScvO2) using predefined
interventions; this protocol is described in Jones et al.6
Patients meeting inclusion criteria were volume resusci-
tated to reach a central venous pressure of ‡ 8 mm Hg
and were intubated and mechanically ventilated as
needed to maintain oxygen saturation measurements
‡ 94%. Arterial pressure transducers were placed and
either norepinephrine or dopamine was infused to
reach an MAP target of 65 mm Hg. Once the MAP tar-
get was reached, patients received transfused packed
red blood cells and dobutamine as needed to maintain
ScvO2 ‡ 70%. At the time that subjects had their central
venous catheter placed, and 24 hours later, blood was
drawn into serum separation tubes (SST) clot tubes (BD
Vacutainer, Franklin Lakes, NJ) and stored at )80C.
Measurements
The complement proteins measured were chosen to
consider the pathway of activation, the extent of global
activation, and the specific production of C5a (Figure 1).
C3 was measured with the Cobas Integra platform
(Roche Diagnostics, Ltd., West Sussex, UK). Other pro-
teins were measured using eOptEIA (BD Biosciences,
San Jose, CA) for C3a and C5a and MicroVue Comple-
ment (Quidel, San Diego, CA) for Bb and C4d. Both
Figure 1. Overview of the complement system components
relevant to the current work. Components in gray boxes are
those for which serum measurements were made. Assayed ele-
ments were chosen to highlight pathway of activation (i.e., C4d
for the classical and MBL pathways, Factor Bb for the alterna-
tive pathway), for assessing the total amount of activation (C3,
C3a), and for the production of the peptide felt to be most phys-
iologically relevant in this context, C5a. MBL = mannose-bind-
ing lectin.
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C3a and C5a are quickly converted to the des-Arg
forms by a number of serum carboxypeptidases; as
these forms are indistinguishable by the assays we
used, in this report we will refer to the parent proteins
and their des-Arg forms collectively as C3a and C5a.
Literature Review to Develop Statistical Prior Proba-
bilities. A formal literature review was undertaken to
establish prior probabilities for Bayesian analysis of our
prospective measurements. The search was conducted
in six databases by a professional clinical librarian
(GKR) in July 2008. Six discrete searches were con-
ducted in each of the databases. No year or language
limits were applied to any of the searches. Efforts were
taken to be as inclusive as possible in the search retrie-
val. The librarian performed minor evaluation of the
articles retrieved to ensure topical (or potentially topi-
cal) relevancy. Of over 800 reports initially identified,
three provided data specifically related to extent of C5a
activation in sepsis or septic shock compared to healthy
controls, and two were suitable for inclusion in our
analysis.7,8
Data Analysis
Because of the availability of previous ICU studies with
similar study designs, we chose a Bayesian, rather than
frequentist, approach. Patient data were analyzed using
the Bayesian package WinBUGS 1.4 (MRC Biostatistics
Unit, Cambridge, UK) with R2WinBUGS serving as the
interface with R.9 Results are reported as means and
95% credible intervals. The Bayesian credible interval is
distinct from the more commonly used frequentist con-
fidence interval (CI). The former is the posterior proba-
bility, given prior expectations and new experimental
data, that the value of a parameter of interest lays
between two bracketing values. The latter is the range
in which one would expect to find an estimate of a
parameter of interest after many repeated, but not actu-
ally conducted, experiments. As our systematic litera-
ture review provided specific prior information about
C5a in septic patients, we used Bayesian methods to
take advantage of those data. In all cases, prior data
(i.e., those data recovered from our literature review)
were assumed to be normally distributed with mean l,
and variance r2, where l also was normally distributed
and r2 was inverse-gamma-distributed. For the prior
probability of C5a among healthy and septic patients,
values were taken from two reports in the literature.
For Schreiber et al.,7 original data were very graciously
provided by Dr. Markus Huber-Lang. For Weinberg et
al.,8 the C5a values were manually extracted from a
scatter plot in the printed manuscript. To combine the
information from the two reports into prior probabili-
ties, the pooled mean for healthy and septic C5a levels
was calculated as the mean of the mean values from
both reports weighted by their precision. The pooled
standard deviation (SD) was calculated as the mean of
the SDs weighted by their sample size. For protein
analyses other than C5a, prior information was not
available, and therefore vague prior probabilities (l = 0,
r = 100) were used in the analysis.10
The WinBUGS Gibbs sampling method was used for
estimation. Three Markov chains, each with 5,000 itera-
tions, were used to generate posterior means and 95%
credible values. A similar strategy, also with vague
priors, was used for linear regression.
RESULTS
Clinical features of the 20 septic patients are shown in
Table 1. In general, the subjects were representative of
community-acquired sepsis. Controls were similar in
age and in sex distribution, although all controls were
of white race. Figure 2 shows the extent of physiologic
abnormalities seen at the time of enrollment (namely,
systolic and central venous pressure and central venous
oxyhemoglobin saturation) and the effect of 24 hours
of resuscitation directed at normalizing systemic and
Table 1
Patient Demographics, Clinical Characteristics, and Physiologic
Measurements
Variable Cases (n = 20)
Controls
(n = 10)
Age, yr (mean ± SD) 55 ± 18.2 49 ± 8*
Race, n (%)






Male 8 (40) 3 (30)




Diabetes mellitus 3 (15)
COPD 3 (15)
End-stage renal disease 1 (5)
Cancer 6 (30)
Indwelling vascular line 1 (5)
Nursing home resident 1 (5)
ED vital signs (mean ± sd)
sBP (mm Hg) 96 ± 24
Pulse (beats ⁄ min) 98 ± 21
RR (breaths ⁄ min) 22 ± 4.7
Temp (F) 99 ± 3.7
O2 sat (%) 97 ± 32.2
CVP (mm Hg) 9 ± 8.0




Suspected source of infection, n (%)
Pulmonary 7 (35)
Urinary tract 5 (25)
Intraabdominal 3 (15)
Skin ⁄ soft tissue 1 (5)
Blood (bacteremia) 1 (5)
Unknown 3 (15)
Hospital outcomes
Hospital days 8 ± 7.1
ICU days 4 ± 4.6
Mortality 3 (15)
CAD = coronary artery disease; COPD = chronic obstructive
pulmonary disease; CVA = cerebrovascular accident;
CVP = central venous pressure; O2 sat = oxygen saturation;
sBP = systolic blood pressure; RR = respiratory rate;
ScvO2 = central venous oxygen saturation; SOFA = sequen-
tial organ failure assessment.
*95% credible interval for difference: )4 to 15 years.
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central venous pressures and ScvO2. Improvements
were seen in both low- and high-SOFA score groups,
although most strikingly in the latter.
Figure 3 compares, between healthy and septic
patients, as well as within septic patients at presenta-
tion and 24 hours after presentation, the concentrations
of each of the complement proteins measured. As
expected, there was significant consumption of C3,
which was present on arrival and slightly worse, on
average, the following day. Elevation was seen in all of
the activation products, with the greatest fold change
(11.3-fold, 95% CI = 10.1 to 13.1) seen in C3a concentra-
tion. Both the classical ⁄ MBL and the alternative path-
ways were activated, with the alternative pathway
marker Factor Bb 6.1-fold (95% CI = 4.4 to 7.7)
increased over healthy controls and the classical ⁄ MBL
marker C4d slightly less increased at 3.5-fold (95%
CI = 2.6 to 4.6). Only 3 of the 20 patients enrolled (15%)
died of their illness, and as would be expected given
our modest sample, no statistically significant differ-
ences were seen in any of the complement proteins in
this group.
An unexpected inverse relationship between initial
SOFA score and initial serum C5a concentration was
noted (slope = )1.0 ng ⁄ ml ⁄ SOFA point, 95% credible
interval = )1.7 to )0.3, r2 = 0.18). The alternative path-
way appeared to explain more C5a variation (slope =
0.8 ng C5a ⁄ ng Bb, 95% credible interval = 0.3 to 1.3,
r2 = 0.24) than did the classical ⁄ MBL pathway (slope =
2.1 ng C5a ⁄ ng C4d, 95% credible interval = 0.4 to 3.9,
r2 = 0.14), although both contributed in a statistically
significant way.
Figure 4 shows the estimated distributions of C5a
concentrations in our series and in the two most com-
parable previously published reports. Data from all
three sources suggest either skewed or possibly multi-
modal distributions of C5a in septic patients. Neither
we nor the authors of the other two articles were able
to statistically discern a relationship between worsen-
ing illness severity and the long upward tail of these
distributions.
DISCUSSION
We report a detailed characterization of C5a dysregula-
tion in patients with community-acquired severe sepsis.
The magnitude of C5a production in these ED patients
prior to treatment was comparable to that seen in pre-
viously reported ICU series when formally considered
with Bayesian methods. Both the classical ⁄ MBL and the
alternative pathways appear to contribute to cascade
activation in vivo, with the latter having a stronger sta-
tistical association with serum C5a concentrations.
A structured resuscitation protocol failed, at 24 hours,
to reverse any of the complement abnormalities seen.
We did not detect significant improvement in any of the
measured complement proteins 24 hours after the onset
of initial treatment designed to quickly correct hypoper-
fusion, ameliorate oxygen debt, and provide antibiotic
coverage. In 2007, Rivers and colleagues11 reported the
impact of structured ED resuscitation on temporal
trends of several circulating mediators in human sepsis.
Most exhibited clearance half-lives of approximately
12 hours, and in several instances clearance was has-
tened by structured resuscitation. In our modest sample,
we did not detect a shift toward resolution in any of the
Figure 2. Results of resuscitation protocol. Patients were
included in the study on the basis of presenting SOFA score (see
text for details). This figure shows the change in three key physi-
ologic measures that both guided the intensity of resuscitation
and reflected its success, the sBP, the central venous pressure,
and the ScvO2. Summary measures are shown, divided by low-
and high-SOFA groups, at presentation (t0) and as the best value
measured over the first full day after resuscitation (t24). Box plots
represent 5th, 25th, 50th, 75th, and 95th percentiles. Asterisks
represent extreme values. Values over the box pairs represent
the mean difference between groups and that difference’s pos-
terior 95% credible interval. See text for details. CVP = central
venous pressure; sBP = systolic blood pressure; ScvO2 = central
venous oxygen saturation.
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complement components we measured at 24 hours. The
reason for the difference between these two findings is
unclear and may relate in part to the strategy used in
the Rivers et al. report to subset patients based on ill-
ness severity. An alternative explanatory hypothesis is
that all of the mediators reported by Rivers et al. were
shed (intercellular adhesion molecule-1 [ICAM-1]) or
secreted (TNF-a, IL-1ra, IL-8, caspase-3) proteins attrib-
utable to inflammatory cells.11 Therapies effective in
quenching cellular inflammatory responses by correct-
ing oxygen debt and acidosis may not be similarly effec-
tive in reducing the activation of the complement
cascade, which once deployed into the circulation, can
proceed in the complete absence of host cells.
Activation of, and exacerbated injury due to, the
complement cascade is recognized in many infectious
and ischemic conditions. In animals, uncontrolled acti-
vation of the system adversely affects cardiovascular,
Figure 3. Serum complement protein concentrations. 20 patients with severe sepsis and 10 healthy controls were studied. (A)
Among septic patients, measurements were made at the onset of resuscitation (t0) and 24 hours later (t24). Box plots represent 5th,
25th, 50th, 75th, and 95th percentiles. Asterisks represent extreme outliers. Values over the box pairs represent the mean difference
between groups and that difference’s posterior 95% credible interval. See text for details. C3 levels were significantly depressed at
presentation and thereafter, and all other measured mediators were significantly elevated in patients over controls. No significant
resolution of these abnormalities was detected 24 hours after the onset of standardized quantitative resuscitation. (B) The mean
fold change over control values of each protein concentration in severe sepsis, by position in the complement pathway. Values
here map to those reflected in the complement pathway shown in Figure 1. 95% credible intervals are reported in the text.
MBL = mannose-binding lectin.
Figure 4. Observed distributions of C5a concentration in previous reports by Schreiber et al.,7 Weinberg et al.,8 and in our data.
Distributions are plotted using Gaussian smoothing. The vertical axis is scaled as to make the curves formal probability density
functions (i.e., their areas equal 1). Individual data points from each source are plotted as rugs beneath (for control patients) or
above (for septic patients) each graph with the exception of the Weinberg control data, for which the original report provided only
a mean and standard deviation, not individual data points. All three data sets reflect a long rightward tail. The rightward shift in
control values of approximately 10 ng ⁄ ml in our data may reflect the use of serum rather than plasma for protein determinations in
the current work.
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respiratory, renal, and coagulation function in sepsis
and other types of shock.12–20 While there is consider-
able interest in C5a as a therapeutic target in human
sepsis, our review of the literature indicates that clinical
experience with this mediator is modest. In none of the
studies identified (nor in the current report) are sample
sizes sufficient to undertake a careful analysis of the
clinical features associated with exuberant pathway
activation. One previous report21 and our own data
appear to indicate an inverse relationship between the
extent of activation and illness severity. A much larger,
prospectively gathered cohort would be helpful.
Regardless of sample size, the relationship between
illness severity and circulating C5a levels is likely to be
complex. C5a can be generated both by encountered
microorganisms and by tissue injured in the inflamma-
tory response to those microorganisms. Removal of C5a
appears to be driven primarily by two cell surface recep-
tors for this anaphylatoxin, C5aR and C5aL2. These
receptors are present on myeloid and nonmyeloid cells
and are intracellularly internalized upon ligand bind-
ing.22 The determination of C5a in any body fluid is
therefore a measurement of one compartment of a
dynamic system that includes uncertainties in the rate of
production and the rate and extent of scavenging.
Future efforts in untangling the role of C5a in human
sepsis will benefit from study designs that incorporate
measures not just of protein levels over time, but that
also attempt to track the state of C5a receptors and the
predominant cell types harboring these receptors over
time. Such strategies will likely require flow cytometry
of surface receptors from critically ill patients, a tech-
nique that poses substantial technical challenges when
being conducted in emergent settings.23
Another important question that we are unable to
address in the current work is the specificity of comple-
ment activation in sepsis compared to other critical ill-
nesses. Existing evidence makes a weak case for the
use of C5a as a biomarker in sepsis. Nevertheless, as
complement activation is known to take place during
several noninfectious serious illnesses, such as acute
injury and nonseptic shock, it is hoped that future work
can also examine this pathway’s presence, and possible
role, in these illnesses as well.
LIMITATIONS
While the magnitude of complement abnormalities
among septic patients compared to healthy individuals
was so great that statistically meaningful differences
were easily detected, our sample size was sufficiently
small to prevent more detailed exploration of relation-
ships between clinical features and the extent and tim-
ing of activation and resolution. There was a difference
in race between cases and controls. Among cases, race
was not related to extent of complement activation.
However, a more complex interaction between race
and activation cannot be excluded.
CONCLUSIONS
Complement activation at the time of initial hospital
presentation is significant in patients diagnosed in the
ED with severe sepsis. Although both the classi-
cal ⁄ mannose-binding lectin and the alternative path-
ways contribute, the latter appears to be the dominant
mechanism. Unlike other mediators that have been
studied in this context, complement activation did not
significantly improve following 24 hours of structured
resuscitation in the ED and intensive care unit.
The authors thank Barbara Smith for her invaluable assistance.
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